Scholars Central

Conference abstract

Dual strategy for treatment of cancer based on development of antiangiogenic carrier for anticancer agent

Authors: Keerti Jain, N. K. Jain

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

In this study poly (propylene) imine (PPI) dendrimers were conjugated peripherally with arginine to mimic the surface structure of an endogenous angiogenesis inhibitor endostatin. Simultaneously the developed surface engineered dendrimers were evaluated as site specific delivery vehicle for anticancer drug, doxorubicin hydrochloride. Synthesis of PPI dendrimers and conjugation of arginine to surface group was confirmed by FTIR, NMR and TEM. Doxorubicin was loaded by equilibrium dialysis method. The developed formulation showed the initial rapid release followed by sustained release characteristics in i n vitro and in vivo studies. The formulation exhibited significant anti-angiogenic activity in the in vivo chick embryo chorioallantoic membrane (CAM) assay and selective uptake by cancer cells in the ex vivo cell uptake studies and in vivo biodistribution studies. Endostatin inhibits angiogenesis by competing for heparan sulfate proteoglycan (HSPG) binding site, which act as co-receptors for some important angiogenic factors including bFGF. Endostatin demonstrates arginine clusters in its structure, which is responsible for binding to HSPG. Arginine conjugated dendrimers showed the anti- angiogenic activity by mimicking the surface structure of endostatin and exhibited the sustained and targeted delivery of anticancer drug owing to the nanometric nature of dendrimer. Clinical evidences suggest that the combination of anti-angiogenic agents with chemotherapy resulted in synergistic anticancer effect. So the results of this study advocate that the developed formulation would prove as a promising strategy in the field of medicine for treatment of cancer as it will attack malignant tissue at two steps, inhibition of angiogenesis and destruction of proliferating cancer cells.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Nanomedicine & Nanotechnology.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Nanomedicine & Nanotechnology
  • SubjectNanotechnology
  • BylineArticles whose byline prints “Keerti Jain”
  • BylineArticles whose byline prints “N. K. Jain”